PCM
IOVA icon

Pinz Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Pinz Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-39,200
Closed -$1.08M – 152
2020
Q2 		$1.08M Buy
+39,200
New +$1.29M 0.49% 94

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Pinz Capital Management's IOVA Position: Q3 2020 in Review

Pinz Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 39,200 shares — an estimated $1.08M sold.

Pinz Capital Management first reported a position in IOVA in Q2 2020 and held it in 1 quarter. The position peaked at $1.08M in Q2 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • Pinz Capital Management reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 39,200 Iovance Biotherapeutics shares in Q3 2020, an estimated $1.08M.
  • Pinz Capital Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Iovance Biotherapeutics position peaked at $1.08M in Q2 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.